Leukemia patients who enroll in LLS's PedAL screening trial and are found to have certain alterations will be directed to receive ziftomenib in a Phase I study.

In 2021, research led by Ryan Flynn, MD, PhD, and his mentor, Nobel laureate Carolyn Bertozzi, PhD, opened a new chapter in biology, characterizing a new kind of player on the cell surface: glycoRNAs.

Pediatric patients with ALL experience, on average, about 15 different symptoms in their chemotherapy journey.

Researchers sought to determine whether MSD HSCT or auto-HSCT would have advantages over chemotherapy in post-remission treatment for patients with AML.

Blood-based proteomic profiling of 251 inflammatory proteins in 543 newly diagnosed patients with acute myeloid leukemia (AML) identified an eight-protein signature that enhances risk stratification.